SCHEMBL3016535

SCHEMBL3016535

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 4/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 4/20 0.43
USP2 O75604 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HTT P42858 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 2/20 0.42
HSD17B10 Q99714 1/20 0.42
ACLY P53396 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008922 0.95 ALDH1A1 (0.50) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3020101 0.93 ALDH1A1 (0.43) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3005635 0.93 KMT2A (0.46) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3653907 0.92 KMT2A (0.48) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3007930 0.91 ALDH1A1 (0.47) LMNAKMT2AMAPTALDH1A1USP2
SCHEMBL3012172 0.90 ALDH1A1 (0.43) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3013082 0.90 ALDH1A1 (0.46) LMNAKMT2AMAPTALDH1A1USP2
SCHEMBL3776753 0.90 ALDH1A1 (0.40) LMNAKMT2AMEN1MAPTTSHR
SCHEMBL3013176 0.90 ALDH1A1 (0.45) LMNAKMT2AMAPTALDH1A1USP2
SCHEMBL3016382 0.90 ALDH1A1 (0.43) LMNAKMT2AMEN1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885KMT2A 2680/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.